Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Antitumor agent
US11376266B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11376266-B2 |
| Application number | US-201716067906-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 5, 2017 |
| Priority date | Jan 6, 2016 |
| Publication date | Jul 5, 2022 |
| Grant date | Jul 5, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula:wherein an average value of n is 4 or larger and 1136 or smaller.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a patient with a tumor, comprising administering an effective amount of water-soluble sulfasalazine, the water-soluble sulfasalazine being a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller. 2. The method according to claim 1 , wherein an average molecular weight of PEG that modifies sulfasalazine is 500 or more and 6,000 or less. 3. The method according to claim 1 , wherein an average molecular weight of PEG that modifies sulfasalazine is 4,000 or more and 6,000 or less. 4. The method according to claim 1 , wherein the water-soluble sulfasalazine is injected to the patient.
Assignees
Inventors
Classifications
- A61K47/60Primary
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
- A61K31/635Primary
having a heterocyclic ring, e.g. sulfadiazine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11376266B2 cover?
- The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula:wherein an average value of n is 4 or larger and 1136 or smaller.
- Who is the assignee on this patent?
- Univ Keio, Tokyo Inst Tech
- What technology area does this patent fall under?
- Primary CPC classification A61K47/60. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).